AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34477275
Drug: Intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous ibuprofen (IV)
Trial: 35389288
Drug: Level 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level 2: Level 1 plus personalized diet and exercise prescription
Trial: 32898698
Drug: Ketamine-lidocaine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine-lidocaine group (0.5 mg/kg ketamine plus 1 mg/kg lidocaine)
Trial: 32898698
Drug: Ketamine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine group (1 mg/kg ketamine)
Trial: 33894834
Drug: Sonelokimab 30
RxNorm normalized name: Sonelokimab
DrugBank: Sonelokimab (DB18843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonelokimab 30 mg
Trial: 33894834
Drug: Sonelokimab 60
RxNorm normalized name: Sonelokimab
DrugBank: Sonelokimab (DB18843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonelokimab 60 mg
Trial: 33894834
Drug: Sonelokimab 120
RxNorm normalized name: Sonelokimab
DrugBank: Sonelokimab (DB18843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonelokimab 120 mg normal load
Trial: 33894834
Drug: Sonelokimab 120
RxNorm normalized name: Sonelokimab
DrugBank: Sonelokimab (DB18843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonelokimab 120 mg augmented load
Trial: 33310293
Drug: Standard neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard neoadjuvant treatment or experimental treatment modified according to interim Ki-67 evaluation
Trial: 34506240
Drug: Codeine 30
RxNorm normalized name: codeine 30 MG
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine 30 mg/acetaminophen 325 mg every 4 hours as needed for severe pain for 4 days
Trial: 34506240
Drug: Oxycodone 5
RxNorm normalized name: oxycodone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 5 mg/acetaminophen 325 mg every 4 hours as needed for severe pain for 4 days
Trial: 34506240
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (codeine and oxycodone)
Trial: 35063882
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy plus concurrent chemoradiotherapy
Trial: 35265234
Drug: UTVOR (volatile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UTVOR (volatile oil of Olibanum and volatile oil of Chuanxiong Rhizoma with ultrasound therapy)
Trial: 36197757
Drug: Ozoralizumab 30
RxNorm normalized name: benralizumab 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozoralizumab 30 mg and 80 mg
Trial: 32048133
Drug: High lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High lactate levels (≥ 2 mmol/l)
Trial: 32048133
Drug: Low lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low lactate levels (< 2 mmol/l)
Trial: 33322963
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group received directly observed therapy of asthma controller medication, medication adjustments, and daily self-management support.
Trial: 34772609
Drug: Chemotherapy (capecitabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (capecitabine, oxaliplatin added an investigator's choice)
Trial: 33793609
Drug: Vestibular rehabilitation
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular rehabilitation with virtual reality using the Wii® console, Wii-Remote and Wii Balance Board, performing balance games for 30 minutes to an hour, twice a week for 10 weeks (total: 20 sessions).
Trial: 33793609
Drug: Vestibular rehabilitation
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular rehabilitation with virtual reality using the Wii® console, Wii-Remote and Wii Balance Board, performing balance games and muscle strength games for 30 minutes to an hour, twice a week for 10 weeks (total: 20 sessions).
Trial: 35949961
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic field (PEMF) therapy (8 Hz, 3.2 mT) in addition to a conventional rehabilitation program
Trial: 35949961
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation program (physical modalities, exercises, and occupational therapy)
Trial: 33078386
Drug: Fenfluramine at
RxNorm normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine at 0.2 mg/kg/d, titrated to a maximum of 0.7 mg/kg/d (or 0.4 mg/kg/d with stiripentol)
Trial: 39028916
Drug: Standard-of-care chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care chemotherapy
Trial: 34252783
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment for youth with co-occurring mental health and substance use concerns
Trial: 33977687
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg) and Atorvastatin (10 mg) once a day for 8 weeks
Trial: 34248001
Drug: 1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine gel treatment
Trial: 35793884
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with western medication
Trial: 34279749
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination carteolol/latanoprost (LCFC)
Trial: 33941629
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (open reduction and internal fixation)
Trial: 32015461
Drug: AVL-3288 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVL-3288 (10 mg)
Trial: 32015461
Drug: AVL-3288 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVL-3288 (30 mg)
Trial: 36301170
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (acupotomy + warm needling)
Trial: 34936267
Drug: Horizontal penetration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horizontal penetration needling at vertigo auditory area and balance area (treatment given once every other day for two courses of treatment)
Trial: 34936267
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no acupuncture and medication)
Trial: 32554067
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg/kg bolus over 10 minutes, followed by 0.5 μg/kg per hour maintenance) with midazolam (0.03 mg/kg)
Trial: 32554067
Drug: Propofol (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (125 μg/kg per minute infusion over 10 minutes with intraoperative boluses of 0.1 μg/kg) and fentanyl (0.8 μg/kg) with midazolam (0.03 mg/kg)
Trial: 32543980
Drug: Cryotherapy spray
RxNorm normalized name: MENTHOL 10.5 g in 100 mL TOPICAL LIQUID [Tidl Full Body Pain Relief Cryotherapy Spray.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryotherapy spray (Cryo‐sp)
Trial: 32267071
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin analog (BI)
Trial: 33616875
Drug: Mid-mixture insulin
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-mixture insulin analog (MMI)
Trial: 34051428
Drug: Flaxseed oil
RxNorm normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed oil (4 g ALA/day)
Trial: 34051428
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (4 g DHA + 0.8 g EPA/day)
Trial: 35623756
Drug: Diabetes Community
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes Community Exercise and Education Programme (DCEP) - twice weekly sessions of exercise and education over 12 weeks, followed by ongoing exercise classes.
Trial: 35907490
Drug: Standard daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard daily dosing of vitamin D
Trial: 35907490
Drug: Loading doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading doses followed by standard daily dosing of vitamin D
Trial: 34423510
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group treated with 30% GA peel at 2 weekly intervals with 5% TXA solution applied twice daily
Trial: 35172878
Drug: Treatment holiday
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment holiday (TH) group: belimumab 10 mg/kg IV discontinued for 24 weeks, then restarted 10 mg/kg IV every 4 weeks for 28 weeks
Trial: 35172878
Drug: Treatment continuation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment continuation (TC) group: continued on belimumab 10 mg/kg IV plus standard therapy every 4 weeks for 52 weeks
Trial: 35172878
Drug: Long-term discontinuation
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term discontinuation (LTD) group: permanently withdrawn from further belimumab treatment
Trial: 35066982
Drug: EGF-containing cream
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGF-containing cream
Trial: 33107666
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) - 10 weekly telephone sessions
Trial: 33140719
Drug: Enhanced upper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced upper limb therapy
Trial: 33184771
Drug: Environmental diffusion
RxNorm normalized name: LUNG DIFFUSION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Environmental diffusion essential oil therapy (EOT) combined with psychotropic drug therapy (group A)
Trial: 33184771
Drug: Psychotropic drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic drug therapy alone (group B)
Trial: 35239778
Drug: Traction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traction therapy
Trial: 33401984
Drug: SMOF Lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMOF Lipid 20% infusion
Trial: 33755235
Drug: Once-weekly selinexor,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly selinexor, bortezomib, and low-dose dexamethasone (XVd)
Trial: 33755235
Drug: Standard twice-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard twice-weekly bortezomib and moderate-dose dexamethasone (Vd)
Trial: 33152284
Drug: POAI (letrozole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POAI (letrozole 2.5 mg per day or anastrozole 1 mg per day for 14 days)
Trial: 38771467
Drug: Ketotifen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (1 mg twice daily for 4 weeks)
Trial: 33080002
Drug: Control (non-tocilizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (non-tocilizumab treatment)
Trial: 35678062
Drug: High-Intensity Laser
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Laser Therapy (HILT) plus Exercise Therapy (ET)
Trial: 35678062
Drug: Low-Intensity Pulsed
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Intensity Pulsed Ultrasound (LIPUS) plus Exercise Therapy (ET)
Trial: 34622567
Drug: liraglutide (≤1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide (≤1.8 mg/d)
Trial: 34622567
Drug: oral antidiabetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral antidiabetic drug (OAD)
Trial: 33726724
Drug: Therapies from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapies from CAM providers
Trial: 33726724
Drug: CAM therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAM therapies from physicians
Trial: 34235821
Drug: Drugs
RxNorm normalized name: herbal drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs
Trial: 34001059
Drug: FOLFIRINOX (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX (oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, irinotecan 150–180 mg/m2, 5‐fluorouracil: 400 mg/m2 then 2400 mg/m2 over 46 h) every 14 days with regorafenib (80 to 160 mg, orally, once daily on days 4 to 10 of each cycle)
Trial: 32927858
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy + Exercise
Trial: 35339280
Drug: Tranilast (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranilast (300 mg daily) for 7 days
Trial: 35339280
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (antiviral therapy only)
Trial: 32644875
Drug: Estradiol (E2)
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol (E2) dose
Trial: 32553417
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with conventional side-vented needle irrigation and ultrasonic activation (Control)
Trial: 34872102
Drug: Peripheral low‐concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral low‐concentration (10 µg/mL) norepinephrine infusion
Trial: 34872102
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline 0.9%) infusion
Trial: 35659704
Drug: Ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 3 mg/kg (ipi3)
Trial: 35659704
Drug: Ipilimumab 10
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 10 mg/kg (ipi10)
Trial: 36037679
Drug: Milvexian (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milvexian (oral small-molecule inhibitor of FXIa)
Trial: 36067616
Drug: R +
RxNorm normalized name: Immune 24 Hour +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R + L (ribociclib plus letrozole)
Trial: 35692220
Drug: Favipiravir +
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Favipiravir + camostat + ciclesonide combination therapy
Trial: 35692220
Drug: Favipiravir monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Favipiravir monotherapy
Trial: 37676977
Drug: Dignity Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dignity Therapy
Trial: 35652769
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL 70% alcohol (CPN20 group)
Trial: 35652769
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL 70% alcohol (CPN40 group)
Trial: 38630551
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks
Trial: 35427471
Drug: Chemotherapy (mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (mFOLFOX6 or FOLFIRI with or without bevacizumab or cetuximab)
Trial: 32671687
Drug: FPG level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPG level 1 (≤ 5.6 mmol/L)
Trial: 32671687
Drug: FPG level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPG level 2 (> 5.6 to ≤ 6.1 mmol/L)
Trial: 32671687
Drug: FPG level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPG level 3 (> 6.1 to ≤ 7.0 mmol/L)
Trial: 33597289
Drug: Bimagrumab 10
RxNorm normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimagrumab 10 mg/kg, 3 mg/kg, 1 mg/kg administered as IV infusions every 4 weeks
Trial: 33597289
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as IV infusions every 4 weeks
Trial: 33597289
Drug: Bimagrumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimagrumab (all doses pooled)
Trial: 35583581
Drug: Wen-Luo-Tong Granules
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wen-Luo-Tong Granules (WLT) plus oral Mecobalamin for 1 week
Trial: 33727797
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of montelukast sodium chewable tablets
Trial: 33727797
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of montelukast sodium chewable tablets
Trial: 34500109
Drug: Concurrent anodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent anodal tDCS over M1 and DLPFC
Trial: 33902546
Drug: Interactive augmented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive augmented reality-based telerehabilitation in conjunction with hospital-based physical therapy for 3 months
Trial: 33902546
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (hospital-based physical therapy in conjunction with a home-based exercise described in a brochure) for 3 months
Trial: 33902546
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (hospital-based physical therapy in conjunction with a home-based exercise described in a brochure)
Trial: 36460017
Drug: Atezolizumab (840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (840 mg intravenously on day 1 and 15) plus vemurafenib (960 mg or 720 mg twice daily orally) and cobimetinib (60 mg once daily orally; 21 days on and 7 days off)
Trial: 36460017
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus vemurafenib (960 mg or 720 mg twice daily orally) and cobimetinib (60 mg once daily orally; 21 days on and 7 days off)
Trial: 36460017
Drug: Atezolizumab (840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (840 mg intravenously on day 1 and 15) plus vemurafenib and cobimetinib
Trial: 32676959
Drug: Extrapleural autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extrapleural autologous blood injection (EPABI) + Intraparenchymal autologous blood patch injection (IABPI), n = 40
Trial: 32676959
Drug: Intraparenchymal autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraparenchymal autologous blood patch injection (IABPI) only, n = 41
Trial: 35554617
Drug: high/fast: 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high/fast: 1.0 mg nicotine delivered over 5 pulsed-infusions, then 15 saline infusions
Trial: 35554617
Drug: high/slow: 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high/slow: 1.0 mg nicotine delivered over 20 pulsed-infusions
Trial: 35554617
Drug: low/fast: 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low/fast: 0.2 mg nicotine delivered over 5 pulsed-infusions, then 15 saline infusions
Trial: 35554617
Drug: low/slow: 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low/slow: 0.2 mg nicotine delivered over 20 pulsed-infusions
Trial: 35554617
Drug: placebo: Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo: Saline delivered over 20 pulsed-infusions
Trial: 35763894
Drug: Multicomponent exercise
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent exercise program (twice-a-week for 3 months)
Trial: 32702363
Drug: Elagolix (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elagolix (300 mg twice a day) with hormonal add-back therapy (1 mg estradiol/0.5 mg norethindrone acetate once a day)
Trial: 36027804
Drug: Classical ayurvedic
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical ayurvedic pharmaceutical form of herbal medicines
Trial: 32562310
Drug: L-EVOO (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-EVOO (250 mg total phenols kg-1 of oil)
Trial: 32562310
Drug: M-EVOO (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-EVOO (500 mg total phenols kg-1 of oil)
Trial: 32562310
Drug: H-EVOO (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H-EVOO (750 mg total phenols kg-1 of oil)
Trial: 34181712
Drug: 21 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 g/d S. cerevisiae fermentation product (SCFP)
Trial: 35551088
Drug: Intervention integrating
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention integrating PGHD with clinician and patient nudges (weekly text-based symptom surveys and passively recorded step counts)
Trial: 34397615
Drug: Intraosseous (IO)
RxNorm normalized name: Io-Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous (IO) prophylactic antibiotics